Oncology Small Molecule Drugs Market Is Anticipated To Surpass Us$ 120 Bn By 2031

7f83b small molecule oncology drugs rake in the revenue

Oncology Small Molecule Drugs  Market size is done based on a triangulation methodology that is primarily based on experimental modelling approaches such as patient-level data or disease epidemiology for any key indications , number of procedures and install base analysis for any equipment to obtain precise market estimations  for the base year as well as in historic data analysis. Bottom-up approach is always used to obtain Oncology Small Molecule Drugs insightful data for the specific country/regions.

The country specific data is again analyzed to derive data at a global level. Specific factors/parameters are considered related to the individual Oncology Small Molecule Drugs market and quantified with insightful rationale.

For More Insights Into The Market, Request a Sample of this Report –https://www.factmr.com/connectus/sample?flag=S&rep_id=3747

Key Takeaways from the Market Study:

  • The global oncology small molecule drugs market is anticipated to add 1.8x value by 2031
  • Oral oncology small molecule drugs generated over US$ 56 Bn in revenue as of 2019
  • By drug class, targeted therapy drugs to reign supreme, capturing nearly 50% revenue
  • Immunomodulating drugs to hold noteworthy share, surpassing US$ 13 Bn by 2031
  • Non small-cell lung cancer (NSCLC) remains core indication area through 2031
  • U.S to account for 50% of global demand, surpassing US$ 30 Bn in 2019
  • China to contribute 55% of overall market revenue across the forecast period

Key Segments Covered

  • Route of Administration
    • Oral Oncology Small Molecule Drugs
    • Injectable Oncology Small Molecule Drugs
  • Drug Class
    • Small Molecule Chemotherapy Drugs
      • Alkylating Drugs
      • Antimetabolites
      • Other Drugs
    • Small Molecule Immunomodulating Drugs
    • Small Molecule Targeted Therapy Drugs
      • Proteasome Inhibitors
      • Tyrosine Kinase Inhibitors
      • mTOR Inhibitors
      • Hormonal Therapy
  • Distribution Channel
    • Oncology Small Molecule Drugs Distribution via Hospital Pharmacies
    • Oncology Small Molecule Drugs Distribution via Retail Pharmacies
    • Oncology Small Molecule Drugs Distribution via Specialty clinics
    • Oncology Small Molecule Drugs Distribution via Online Pharmacies
  • Indication    
    • Oncology Small Molecule Drugs  for Non-small Cell Lung Cancer
    • Oncology Small Molecule Drugs  for Renal Cell Carcinoma
    • Oncology Small Molecule Drugs  for Breast Cancer
    • Oncology Small Molecule Drugs  for Prostate Cancer
    • Oncology Small Molecule Drugs  for Multiple Myeloma
    • Oncology Small Molecule Drugs  for Melanoma
    • Oncology Small Molecule Drugs  for Lymphoma
    • Oncology Small Molecule Drugs  for Leukaemia
    • Oncology Small Molecule Drugs  for Other Indications

Key Companies Profiled

  • Novartis AG
  • Pfizer Inc.
  • Amgen Plc.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Bayer AG
  • Incyte Corporation
  • Celgene Corporation
  • AstraZeneca Plc.
  • Exelixis Inc.
  • Millennium Pharmaceuticals Inc. (Takeda)

Leave a Reply

Your email address will not be published.